Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 NOV 23 ... a Special Protocol Assessment on the design of a Phase 3 trial for multiple myeloma. - August 17, 2009. Disclosure of results for two Phase 3 studies with ...
2009 NOV 23 ... million in milestones, as well as royalties related to the commercialization of multiple myeloma and other B-cell cancer treatments Reported a 51% increase in FAMILION ...
2009 NOV 23 ... from monoclonal gammopathy of undetermined significance (MGUS) to multiple myeloma (MM) is thought to be associated with changes in immune processes. We have therefore ...
2009 NOV 23 ... Following our announcements of an SPA for the Phase 3 trial of perifosine in multiple myeloma, and exciting long-term safety and efficacy data for Zerenex, we solidified our balance ...
2009 NOV 23 ... and clinical data and will report important new results in indications such as multiple myeloma, non-Hodgkin's lymphoma, chronic lymphocytic leukemia, acute myeloid leukemia and ...
2009 NOV 23 ... single agent and combination studies of pralatrexate in Burkitt's lymphoma, multiple myeloma, specific indolent lymphomas, ovarian cancer, head and neck cancer, prostate cancer, ...
2009 NOV 23 ... B lymphocytes sharing identical, rearranged IGH-CDR3 sequences with the patient's myeloma cells, have been detected in the peripheral blood of patients with multiple...
2009 NOV 23 ... Pathology International. According to recent research from Okayama, Japan, "Plasma cell myeloma is a frequent hematogeneous disorder that occurs mainly in older people. Not only bone ...
2009 NOV 23 ... the carfilzomib development program in patients with relapsed and refractory multiple myeloma. Onyx Pharmaceuticals has previously announced its intent to acquire Proteolix Inc. ...
2009 NOV 23 ... that it has received additional funding support for serving patients with multiple myeloma through its Co-Pay Relief Program (CPR). PAF's Co-Pay Relief Program ...
2009 NOV 23 ... According to recent research published in the journal Cancer Cell, "Multiple myeloma (MM) remains incurable despite novel therapies, suggesting the need for further ...
2009 NOV 23 ... T cell clones are stimulated after thalidomide therapy in patients with multiple myeloma,' is the subject of a report. "The expanded T cell clones are associated with a ...
2009 NOV 23 ... a number of hematological and solid cancers, including malignant melanoma, lymphoma, myeloma, and non-small cell lung cancer. These studies suggest that antigen-loaded DC ...
2009 NOV 23 ... Salinispora tropica is a promising drug candidate for the treatment of multiple myeloma and mantle cell lymphoma." "Using a comprehensive approach that combined ...
2009 NOV 23 ... Research findings, 'Identification of a novel microRNA cluster miR-193b-365 in multiple myeloma,' are discussed in a new report. According to recent research from the United States, ...
2009 NOV 23 ... pre-clinical stability and biological activity data on SNS-01, Senesco's multiple myeloma drug candidate, at the 2009 American Association for Cancer Research (AACR)-National ...
2009 NOV 23 ... New therapies are in testing for ATTR, whereas those for AL have followed multiple myeloma, leading to improved survival. Challenges of diagnosing and caring for patients with ...
2009 NOV 16 ... (DFCI), is Chief of the Division of Hematologic Neoplasia, Director of the Lipper Myeloma Center and Lebow Institute for Myeloma Therapeutics, ...
